Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2007-03-13
2007-03-13
O'Hara, Eileen (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S133100, C424S141100, C424S142100, C424S145100, C514S012200
Reexamination Certificate
active
10424658
ABSTRACT:
A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.
REFERENCES:
patent: 5843725 (1998-12-01), Sledziewski et al.
patent: 5945511 (1999-08-01), Lok et al.
patent: 6610286 (2003-08-01), Thompson et al.
patent: 99/03982 (1999-01-01), None
patent: 99/27103 (1999-06-01), None
patent: 99/46379 (1999-09-01), None
patent: 00/42189 (2000-07-01), None
Mijares et al. Molecular Pharmacology, 2000, vol. 58, pp. 373-379.
E. Choy, Cytokine, 2004, vol. 28, pp. 158-161.
Borrebaeck et al. Current Opinion in Pharmacology, 2001, vol. 1, pp. 404-408.
Rich et al., “Cytokines: IL-20—a new effector in skin inflammation,”Current Biology, 11(13):R531-R534, 2001.
Blumberg et al., “Interleukin 20: Discovery, Receptor Identification, and Role in Epidermal Function,”Cell104:9-19, 2001.
McKinnon et al., “Strategies for the Discovery of Cytokine Receptor Antagonists,”Drug News and Perspectives9:389-398, 1996.
Mohler et al., “Immunotherapeutic Potential of Soluble Sytokine Receptors in Inflammatory Disease,”FASB J. US Fed of American Soc. For Experimental Biology, 6(4):A1123, 1992.
Davis, et al., “Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning,”Cell87:1161-1169, 1996.
Dynan et al., “Control of eukaryotic messenger RNA synthesis by sequence-specific DNA-binding proteins,”Nature316:774-778, 1985.
Blumberg Hal
Chandrasekher Yasmin A.
Foster Donald C.
Thompson Penny
Xu Wen-feng
Hamud Fozia
O'Hara Eileen
Walker Shelby J.
ZymoGenetics Inc.
LandOfFree
Method for treating inflammation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating inflammation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating inflammation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3727219